Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways by Osborn, Maire F. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
RNA Therapeutics Institute Publications RNA Therapeutics Institute 
2019-02-20 
Hydrophobicity drives the systemic distribution of lipid-
conjugated siRNAs via lipid transport pathways 
Maire F. Osborn 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/rti_pubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Biochemical Phenomena, Metabolism, and 
Nutrition Commons, Biochemistry, Biophysics, and Structural Biology Commons, Genetics and Genomics 
Commons, and the Nucleic Acids, Nucleotides, and Nucleosides Commons 
Repository Citation 
Osborn MF, Coles AH, Biscans A, Haraszti RA, Roux L, Davis SM, Ly S, Echeverria D, Hassler MR, Godinho 
B, Nikan M, Khvorova A. (2019). Hydrophobicity drives the systemic distribution of lipid-conjugated 
siRNAs via lipid transport pathways. RNA Therapeutics Institute Publications. https://doi.org/10.1093/
nar/gky1232. Retrieved from https://escholarship.umassmed.edu/rti_pubs/55 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in RNA Therapeutics 
Institute Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
1070–1081 Nucleic Acids Research, 2019, Vol. 47, No. 3 Published online 8 December 2018
doi: 10.1093/nar/gky1232
Hydrophobicity drives the systemic distribution of
lipid-conjugated siRNAs via lipid transport pathways
Maire F. Osborn1,2,*,†, Andrew H. Coles 1,2,†, Annabelle Biscans1,2, Reka A. Haraszti1,2,
Loic Roux1,2, Sarah Davis1,2, Socheata Ly 1,2, Dimas Echeverria1,2, Matthew R. Hassler1,2,
Bruno M.D.C. Godinho1,2, Mehran Nikan1,2 and Anastasia Khvorova1,2,*
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA and 2Department of
Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Received June 14, 2018; Revised November 26, 2018; Editorial Decision November 27, 2018; Accepted December 06, 2018
ABSTRACT
Efficient delivery of therapeutic RNA beyond the
liver is the fundamental obstacle preventing its clini-
cal utility. Lipid conjugation increases plasma half-
life and enhances tissue accumulation and cellu-
lar uptake of small interfering RNAs (siRNAs). How-
ever, the mechanism relating lipid hydrophobicity,
structure, and siRNA pharmacokinetics is unclear.
Here, using a diverse panel of biologically occurring
lipids, we show that lipid conjugation directly mod-
ulates siRNA hydrophobicity. When administered in
vivo, highly hydrophobic lipid-siRNAs preferentially
and spontaneously associate with circulating low-
density lipoprotein (LDL), while less lipophilic lipid-
siRNAs bind to high-density lipoprotein (HDL). Lipid-
siRNAs are targeted to lipoprotein receptor-enriched
tissues, eliciting significant mRNA silencing in liver
(65%), adrenal gland (37%), ovary (35%), and kidney
(78%). Interestingly, siRNA internalization may not
be completely driven by lipoprotein endocytosis, but
the extent of siRNA phosphorothioate modifications
may also be a factor. Although biomimetic lipoprotein
nanoparticles have been explored for the enhance-
ment of siRNA delivery, our findings suggest that
hydrophobic modifications can be leveraged to in-
corporate therapeutic siRNA into endogenous lipid
transport pathways without the requirement for syn-
thetic formulation.
INTRODUCTION
For over a decade, the underlying obstacle preventing
the widespread clinical use of small interfering RNA
(siRNA)-based therapies has been efficient and safe in
vivo delivery. siRNAs are large (∼14 kDa), polyanionic
macromolecules that require extensive modifications to
improve their inherently-poor pharmacological properties
(e.g. plasma half-life of<5min before renal excretion) (1,2).
Lipid- and polymer-based nanoparticles, which are effec-
tive transfection agents in vitro, can prolong circulation time
and improve stability and bioavailability in vivo. However,
nanoparticle delivery is typically limited to clearance or-
gans with fenestrated and/or discontinuous endothelium
(e.g. liver, spleen and certain tumors). Moreover, nanopar-
ticles can interact with opsonin proteins that enhance clear-
ance by macrophage phagocytosis.
Molecular-scale delivery of siRNAs with small target-
ing ligands, cell-penetrating peptides, or lipid conjugates
may be a simple and effective alternative to nanocarrier-
based methods. The most clinically-advanced siRNA con-
jugate, trivalent N-acetylgalactosamine (GalNAc)-siRNA,
binds to the asialoglycoprotein receptor on hepatocytes
with high selectivity, and triggers potent and durable (∼6
months) gene silencing in patients (3,4). The second major
class of molecular siRNA conjugates are lipids, which have
been shown to enhance circulation time and promote lo-
cal and systemic delivery and efficacy. Cholesterol-modified
siRNA, one of the first reported lipid conjugates, silences
liver apolipoprotein B (ApoB) expression at high doses (50
mg kg−1), while-tocopherol and fatty acid conjugates have
also shown potential for liver delivery and gene silencing
(5–7). Productive internalization of cholesterol-conjugated
siRNAs hinges on its interactions with circulating lipopro-
teins and tissue receptors (6). However, the relationship be-
tween the chemical composition of lipid conjugates and
siRNA pharmacology has not been well characterized.
In order to define design parameters for optimizing ther-
apeutic oligonucleotide delivery, we investigated the influ-
ence of structurally diverse lipids on conjugate-mediated
siRNA biodistribution, efficacy, and safety in vivo. These
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studies were enabled by the use of a clinically-validated,
chemically-modified siRNA scaffold that is nuclease resis-
tant and metabolically stable (8). Here, we demonstrate
that lipid conjugation modulates the hydrophobicity of
hsiRNA (hydrophobically modified siRNAs). We present
evidence suggesting that oligonucleotide hydrophobicity
governs pharmacokinetic behavior by driving selective, in
situ incorporation into endogenous lipoprotein pathways.
Lipid modification also enables potent siRNA-mediated
mRNA silencing in lipoprotein receptor-enriched tissues,
including liver, adrenal gland, ovary and kidney. These data
suggest that hydrophobicity likely directs the rank-order tis-
sue distribution of lipidic oligonucleotide conjugates that
may otherwise be intended to be specifically receptor- or
cell-targeting.
MATERIALS AND METHODS
Oligonucleotide synthesis
Oligonucleotideswere synthesized using standard andmod-
ified (2′-fluoro, 2′-O-methyl) phosphoramidite, solid-phase
synthesis conditions using aMerMade 12 (BioAutomation)
and Expedite ABI DNA/RNA synthesizer (ABI 8909).
Oligonucleotides were removed from controlled pore glass
(CPG), deprotected, and HPLC purified as described pre-
viously (8–10). Ion exchange was performed on purified
oligonucleotides using a Hi-Trap cation exchange column.
The identity of oligonucleotides was established by LC-MS
analysis (Waters Q-TOF premier). Relative degree of hy-
drophobicity of sense strands was assayed by reverse-phase
HPLC (Waters Symmetric 3.5 m, 4.6 × 75 mm column)
using a 0–100% gradient over 15 min at 60◦C with 0.1%
TEAA in water (eluent A) and 100% acetonitrile (eluent B).
Peaks were monitored at 260 nm.
Oligonucleotide delivery
HeLa cells were plated in DMEM containing 6% FBS
at 10,000 cells per well in 96-well tissue culture plates.
hsiRNA was diluted to twice the final concentration in
OptiMEM (Gibco), and mixed 1:1 with Lipofectamine
RNAiMAX Transfection Reagent (Invitrogen) (final trans-
fection reagent concentration = 0.3 l/25 l/well). 50 l-
diluted hsiRNA was added to 50 l of cells, resulting in a
final concentration of 3% FBS. Cells were incubated for 72
hours at 37◦C and 5% CO2. For all in vivo studies, lipid-
hsiRNAs were delivery without a transfection reagent.
mRNA quantification
mRNA was quantified using the QuantiGene 2.0 Assay
(Affymetrix) as described previously (8). Briefly, cells were
lysed in 250 l-diluted lysis mixture with Proteinase K
(Affymetrix) for 30 min at 55◦C prior to mRNA quantifi-
cation. Tissue punches (∼5 mg) were homogenized in 300
l of Homogenizing Buffer (Affymetrix) with proteinase K
in 96-well plate format using a TissueLyser II (Qiagen). This
method is described in detail in Coles et al (11).
Mouse studies
All animal procedures were approved by the University of
Massachusetts Medical School Institutional Animal Care
and Use Committee (IACUC, protocol number A-2411).
Mice (FVB/NJ) were 6–10 weeks of age at the time of ex-
periments. All animals were kept on a 12-h light/dark cy-
cle in a pathogen-free facility with food and water ad libi-
tum. For imaging and mRNA-silencing studies, mice were
injected subcutaneously (SC, interscapular, between shoul-
ders) or intravenously (IV, via tail vein) with 10–20 mg
kg−1 of Cy3-labeled oligonucleotides (see figure captions for
details). After 4 h-1 week, mice were deeply anesthetized
with 0.1% Avertin and transcardially perfused with a 4%
paraformaldehyde solution in phosphate-buffered saline,
pH 7.2. Tissues were collected and incubated overnight
at 4◦C in either 10% formalin for subsequent imaging or
RNALater (Ambion) for subsequent mRNA quantifica-
tion. Tissues were processed as described previously (8).
Fluorescence microscopy experiments
All fluorescence images were acquired with a Leica
DM5500microscope fitted with aDFC365 FX fluorescence
camera. After image acquisition, images were exported in
16-bit TIFF format from the Leica LAS X software and
processed in Fiji v1.51n (12) to quantify the kinetics of oligo
uptake into cells. Briefly, the freehand tool was used toman-
ually select individual cells and themean fluorescence inten-
sity was obtained by using the ‘Measure’ function. Back-
ground fluorescence was corrected for by measuring the
mean fluorescence of an area with no cells and subtract-
ing this value from the cellular fluorescence intensity. The
histology of the liver is well defined, and cell structure fea-
tures can be used to identify different cell types, which are
confirmed by immunostaining (13).The major cell types in
liver––hepatocytes (∼52%), Kupffer cells (∼18%), and en-
dothelial cells (∼22%)––are easily defined by their distinct
morphological features.Hepatocytes are large cells and pos-
sess large nuclei, most of which are tetraploid. Endothelial
cells are smaller, elongated cells that surround vessels. Kupf-
fer cells are the smallest cell type and are characterized by
dense nuclei.
Peptide nucleic acid (PNA) hybridization assay
Tissue accumulation of lipid-conjugated hsiRNAs was
quantified as described previously (8,14). Briefly, tissues
were lysed inMasterPure tissue lysis solution (EpiCentre) in
the presence of proteinase K (2 mg/ml) (Invitrogen) using a
TissueLyser II (Qiagen) (∼10mg tissue per 100l lysis solu-
tion). Sodium dodecyl sulfate (SDS) was precipitated with
KCl (3 M) and pelleted at 5000 × g. hsiRNAs presented
in the cleared supernatant was hybridized to a Cy3-labeled
PNA that was fully complementary to guide strand (PN-
ABio) and injected on a DNAPac PA100 anion exchange
column (Thermo Fisher). Cy3 fluorescence was monitored
at 570 nm.
Lipoprotein size exclusion chromatography
For lipoprotein profiling, mice were injected intravenously
with 20 mg kg−1 of Cy3-labeled oligonucleotides. After 15
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minutes, whole mouse blood (∼500 l) was collected in a
sterile EDTA-coated tube following cheek incision with a
lancet. Samples were spun at 10,000 RPM for 10 minutes
at 4◦C. 50 l of serum was directly injected on Superose
6 Increase 10/300 size exclusion column (GE Healthcare).
Oligonucleotide migration was monitored by Cy3 fluores-
cence at 570 nm, and lipoprotein protein content was mon-
itored by absorbance at 280 nm.
Statistical analysis
Data were analyzed using GraphPad Prism 6 soft-
ware. IC50 curves were fitted using log(inhibitor) versus
response––variable slope (four parameters). For Figure
4, statistics were calculated using one-way ANOVA with
Tukey’s test for multiple comparisons, with significance cal-
culated relative to saline control-injected animals. For Fig-
ure 5, statistics were calculated using an unpaired, two-
tailed t-test.
RESULTS
Design and synthesis of structurally-diverse lipid-hsiRNA
conjugates
To evaluate the impact of lipid conjugation on the phar-
macological properties of oligonucleotides, we synthe-
sized a panel of structurally diverse conjugates using a
hydrophobically-modified siRNA scaffold, termed hsiRNA
(Figure 1A, 1B) (9,10,15). This scaffold consists of a 20-
nucleotide (nt) antisense (guide) strand and a 15-nt sense
(passenger) strand, and contains alternating 2′-O-methyl
and 2′-fluoro sugar modifications (16). The 5′-end of the
antisense strand bears a terminal (E)-vinylphosphonate
modification that increases siRNA tissue accumulation, ex-
tends the duration of silencing activity, and shields oligonu-
cleotides from 5′-to-3′ exonucleases (14,17–19). The termi-
nal nucleotide backbones are fully phosphorothioated to
further inhibit exonuclease-mediated degradation and to
promote cellular internalization (20). These extensivemodi-
fications are essential for evaluating conjugate-mediated de-
livery in vivo because partially-modified or unmodified siR-
NAs are rapidly degraded and cleared (8).
Previous studies have identified the 3′-end of the sense
strand as an optimal position for conjugate attachment,
with minimal effect on siRNA-RISC (intracellular RNA-
induced silencing complex) loading (10,21). Therefore, we
designed cholesterol (Chol), lithocholic acid (LCA), do-
cosahexaenoic acid (DHA), and docosanoic acid (DCA)
conjugates to attach through a commercially available
carbon-based linker to the 3′-end of the sense strand via
an amide bond (Figure 1A). hsiRNA conjugates were syn-
thesized on a functionalized solid support bearing each in-
dividual lipid moiety using standard solid-phase oligonu-
cleotide synthesis and deprotection protocols (see Meth-
ods). Synthesized oligonucleotides were then purified and
characterized by high-performance liquid chromatography
(HPLC) and liquid chromatography–mass spectrometry
(LC–MS), respectively. All oligonucleotide sequences and
chemical modification patterns used in this study are re-
ported in Supplementary Table S1.
To evaluate the impact of lipid conjugation on hsiRNA
hydrophobicity, we analyzed Chol-hsiRNA, DCA-
hsiRNA, DHA-hsiRNA, LCA-hsiRNA and unconjugated
hsiRNA by reverse-phase HPLC and measured reten-
tion times (Figure 1C). Here, a longer retention time
correlates with greater affinity for the hydrophobic (C18)
stationary phase. Unconjugated hsiRNAs eluted relatively
quickly (5.7 min), followed by LCA-hsiRNA (7.7 min),
DHA-hsiRNA (8.5 min), DCA-hsiRNA (11.1 min), and
Chol-hsiRNA (11.5 min). This result indicates that DCA-
and Chol-hsiRNAs are more hydrophobic than DHA-,
LCA-, or unconjugated hsiRNAs. The nature of the lipid
conjugate has a clear impact on overall hydrophobicity. In
general, an increase in length causes an increase in overall
hydrophobicity. By contrast, an increase in the degree of
unsaturation makes compounds less hydrophobic. Reten-
tion times did not directly correlate with the predicted
partition coefficients of the free lipids (Supplementary
Table S2), suggesting that lipid orientation and conjugation
position influence overall siRNA hydrophobicity.
To assess the effect of lipid conjugation on RISC loading
and siRNA silencing efficiency in vitro, we transfected each
lipid-hsiRNA into HeLa cells and measured mRNA levels
of a well-validated housekeeping gene, cyclophilin B (PPIB)
(Figure 1D). Calculated half-maximal inhibitory concen-
trations (IC50s) ranged from 4.9× 10−11 to 1.2× 10e−10 M,
confirming that conjugation at the 3′-end of the sense strand
does not substantially affect RNAi potency (Figure 1E).
In summary, we successfully synthesized a panel of lipid-
hsiRNA conjugates with varying degrees of hydrophobicity
that retain gene silencing activity in vitro.
Lipid conjugation reduces hsiRNA kidney exposure and pro-
motes broad biodistribution
To evaluate the biodistribution of each lipid-hsiRNA con-
jugate in vivo, we administered Cy3-labeled lipid-hsiRNAs
into mice by a single, subcutaneous injection (n = 2, 20
mg kg−1) and measured fluorescence distribution after 48
h. As lipid-hsiRNA hydrophobicity increased, we observed
a clear, progressive reduction in kidney accumulation and
an increase in liver retention (Figure 2A). We confirmed
this result using a peptide-nucleic acid (PNA) hybridiza-
tion assay, which measures hsiRNA antisense strand con-
centration in tissue lysate by HPLC. Unconjugated hsiR-
NAs were subject to acute renal clearance after adminis-
tration and reached peak tissue concentrations of ∼1300
ng hsiRNA/mg kidney (Figure 2B). As lipid-hsiRNA hy-
drophobicity increased, kidney accumulation decreased
over 18-fold (peak concentration of ∼70 ng hsiRNA/mg
kidney for Chol-hsiRNA). Our findings agree with pre-
vious pharmacokinetic analyses of lipid-conjugated hsiR-
NAs, which found that the initial distribution half-life of
Chol-hsiRNA was 33–35 min, but was only 15–17 min for
unconjugated hsiRNA (22). Moreover, the total exposure
over time (area under the curve; AUC) increased >10-fold
for Chol-hsiRNA compared to unconjugated hsiRNA (22).
Unlike the kidney, oligonucleotide concentrations in the
liver increased with increasing hydrophobicity of the lipid
conjugate (∼75 ng mg−1 for unconjugated hsiRNA up to
∼715 ng mg−1 for Chol-hsiRNA). Lipid conjugation also
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Figure 1. Synthesis and biophysical characterization of lipid-hsiRNA conjugates. (A) Chemical structures of lipid-hsiRNA conjugates. (B) Modification
pattern and molecular model of lipid-hsiRNAs. (C) HPLC traces of lipid-hsiRNAs following reverse phase column chromatography. (D) HeLa cells were
incubated withPPIB-targeting hsiRNAs at concentrations shown for 72 h.PPIBmRNA levels were measured using QuantiGene (Affymetrix), normalized
to housekeeping HPRT1 (hypoxanthine phosphoribosyltransferase 1) mRNA levels, and presented as percent of untreated control (n = 3, mean ± SD).
UNT – untreated cells. (E) Plotted IC50 values determined from the best-fit curves in (D).
Figure 2. Systemic biodistribution and tissue accumulation of lipid-hsiRNA conjugates. Biodistribution of lipid-hsiRNAs 48 h after a single, subcutaneous
injection (n = 3 mice, 20 mg kg−1). (A) Kidney and liver distribution of lipid-conjugated hsiRNAs. Cy3-labeled lipid-hsiRNAs (red), nuclei stained with
DAPI (blue). (B) Guide strand quantification of Cy3-labeled lipid-hsiRNAs by a PNA hybridization-based assay. Data presented as mean ± SD.
enabled delivery beyond the liver and kidney, supporting
conjugate-mediated siRNA accumulation in lung, heart,
adrenal gland, spleen, adipose tissue, and femoral muscle
(Figure 2B).
Hydrophobicity governs the interaction between lipid-
hsiRNAs and serum proteins
To investigate potential mechanism(s) governing the asso-
ciation between lipid-siRNA hydrophobicity and biodis-
tribution, we measured the affinity of lipid-siRNAs to-
ward plasma constituents both in vitro and in vivo. Bind-
ing to albumin, a permissive host for both endogenous
and exogenous ligands (23), has been proposed to improve
the pharmacokinetics of lipid-conjugated oligonucleotides
(7). Thus, we measured the affinity of Cy3-labeled lipid-
hsiRNAs and bovine serum albumin (BSA) in vitro us-
ing native gel electrophoresis (Supplementary Figure S1).
Unmodified hsiRNA did not associate with BSA to any
measureable degree. However, all lipid-hsiRNA conjugates
formed stable complexes with BSA, and exhibited dose-
dependentmigration shifts with increasing albumin concen-
tration. We observed a direct correlation between hsiRNA
hydrophobicity and BSA binding, with DCA-hsiRNA and
Chol-hsiRNA exhibiting the highest affinities (Kd ∼ 120
and 164 M, respectively).
To more precisely characterize the behavior of lipid-
conjugated siRNAs in the circulation, we used high-
resolution size exclusion chromatography (SEC) tomeasure
the interaction between oligonucleotides and circulating
proteins in mouse serum. Previous reports have suggested
that sterol-, bile salt-, and fatty acid-siRNAs are capable
of associating with both albumin and lipoproteins in the
bloodstream (6). Thus, we used SEC to define relative size
zones associatedwith very low-density lipoprotein (VLDL),
low-density lipoprotein (LDL), and high-density lipopro-
tein (HDL) particles, in addition to small proteins (predom-
inantly albumin) from mouse serum (Figure 3A). Peak as-
signments were confirmed by measuring cholesterol con-
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Figure 3. Lipoprotein binding profiles of lipid-conjugated hsiRNAs. (A)
Mouse serum protein distribution following size exclusion chromatogra-
phy (SEC). Red shading: VLDL; purple shading: LDL; dark-blue shad-
ing: HDL; light-blue shading: albumin; green shading: no protein. (B) Re-
tention times of Cy3-labeled lipid-hsiRNAs following SEC. (C) Average
retention times of Cy3-labeled lipid-hsiRNAs in mouse serum, 15 minutes
after IV injection (n = 2). Peak shifts indicate serum protein association.
(D) Summary of peak integrations of lipoprotein binding profiles for a va-
riety of lipid-hsiRNAs.
tent in isolated fractions (Supplementary Figure S2). As-
sessment of the serum SEC profiles of wild-type (FVB/NJ)
male and female animals (Supplementary Figure S2) re-
vealed no apparent sex-dependent differences in lipopro-
tein peak assignment. Therefore, we performed subsequent
analyses in female animals only.
To determine if lipid-hsiRNAs form stable complexes
with lipoprotein particles or albumin in vivo, we first mea-
sured baseline retention times of free Cy3-labeled unconju-
gated and lipid conjugated-hsiRNAs (Figure 3B). The un-
bound forms of unconjugated hsiRNA, LCA-hsiRNA, and
DHA-hsiRNA eluted at 62.9 min as a single peak. Un-
bound DCA-hsiRNA and Chol-hsiRNA eluted as a dou-
blet, with peaks at both 62.9 and 65.8min. The presence of a
doublet may reflect a propensity for these two hydrophobic
species to form reversible macromolecular structures un-
der non-denaturing conditions. Next, we analyzed serum
samples from mice injected intravenously with Cy3-labeled
Chol-siRNA,DCA-siRNA,DHA-siRNA, LCA-siRNAor
unconjugated siRNA (n = 2, 20 mg kg−1). Given the av-
erage elimination half-lives of Chol-hsiRNA and unconju-
gated hsiRNA (22), we collected serum 15 min after injec-
tion. By monitoring the baseline shift in hsiRNA fluores-
cence signal, we determined that each lipid conjugate has
a unique lipoprotein binding signature in vivo (Figure 3C).
In direct contrast to our in vitro results, we discovered that
lipid-hsiRNA conjugates do not significantly associate with
albumin in serum, likely due to the presence of higher affin-
ity chaperones, such as lipoproteins. Unconjugated hsiR-
NAs did not associate with any serum components andwere
rapidly excreted into the urine (Figures 2A and 3C). LCA-
hsiRNA associated predominantly with HDL (50.4% of to-
tal binding) and albumin (32.2%), with residual binding to-
wards VLDL (12.2%) and LDL (5.3%). DHA-hsiRNA ex-
hibited a stronger affinity for HDL (80.5%), with lesser co-
migration with albumin (14.9%), LDL (3.7%) and VLDL
(1%) peaks. Conversely, DCA-hsiRNA and Chol-hsiRNA
were predominantly bound to LDL (65% and 82%, respec-
tively), with residual binding to VLDL and HDL. Peak in-
tegrations (Figure 3C) are summarized in Supplementary
Table S3.
To further investigate the similarity between the lipopro-
tein binding profiles and degree of hydrophobicity of siR-
NAs, we employed the same SEC methodology to ana-
lyze an expanded panel of lipid-hsiRNA conjugates. As de-
scribed previously, we performed SEC-based profiling of
lipoprotein-hsiRNA binding and plotted these data as a
function of relative lipid-hsiRNA hydrophobicity (Figure
3D; Supplementary Table S3; Biscans et al., 2018, NAR
in this issue). We observed a strong correlation between
hsiRNA hydrophobicity and segregation into albumin,
HDL, and LDL peaks. Our findings suggest that oligonu-
cleotide hydrophobicity can be engineered to achieve pre-
dictable and stepwise partitioning into different lipid trans-
port pathways in vivo.
Lipid-hsiRNAs elicit sustained systemic in vivo gene silencing
after a single injection
Given that lipid-hsiRNAs predominantly complexed with
circulating lipoproteins after systemic administration, we
assessed the cell-specific distribution and gene-silencing
efficacy of lipid-hsiRNAs in tissues that are enriched in
lipoprotein receptors. For all tissues, cell-specific distri-
bution of hsiRNAs was measured 48 h after a single,
subcutaneous injection into mice (n = 3, 20 mg kg−1).
Gene-silencing efficacy was determined by quantifyingPpib
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mRNA levels one week after a single, subcutaneous injec-
tion of Ppib-targeting hsiRNAs (n = 6, 20 mg kg−1).
Liver. LDL is the principal intercellular transporter of
cholesterol, and LDL receptors (LDLR) are abundantly
expressed on liver hepatocytes, adrenal cortex, bronchial
epithelial cells, and adipocytes. We first monitored cell
tropism in the liver and found that LDL-associated oligonu-
cleotides (Chol- and DCA-hsiRNA) were readily visual-
ized within cytoplasmic foci in liver hepatocytes (Figure
4A, open arrows), while HDL- and albumin-associated
hsiRNAs (DHA-, LCA-, and unconjugated hsiRNA) were
undetectable (Figure 4A, open arrows). By contrast, we
did observe oligonucleotide internalization in Kupffer cells
(stellate macrophages) for all five hsiRNAs (Figure 4A,
closed arrows). This result is consistent with what is known
regarding the mononuclear phagocyte (reticuloendothelial)
system as a first response against exogenous substances, in-
cluding siRNAs and antisense oligonucleotides. We con-
firmed our findings for Chol-hsiRNA, DCA-hsiRNA, and
DHA-hsiRNA by FACS, noting hsiRNA accumulation in
28–59% percent of endothelial cells and 18–49% of Kupf-
fer cells, respectively (n = 3, 10 mg kg−1, Supplementary
Figure S3). Next, we correlated hsiRNA accumulation with
Ppib mRNA levels. As expected, Chol-hsiRNA and DCA-
hsiRNA displayed the highest activity, reducing liver Ppib
mRNA expression by 59% and 65%, respectively (Figure
4B, Supplementary Table S4). Unconjugated hsiRNA re-
duced Ppib mRNA levels by 39% (Figure 4B). We did not
observe a reduction in PpibmRNA after administration of
non-targeting control hsiRNAs (n = 6, 20 mg kg−1, Sup-
plementary Figure S4). We also did not observe significant
upregulation of liver toxicity biomarkers, alkaline phos-
phatase (ALP) and alanine aminotransferase (ALT), in the
blood (Supplementary Figure S5).
Adrenal gland. Circulating lipoproteins contribute over
half of the cholesterol required for steroidogenesis in
adrenocortical cells (24). Therefore, we wanted to assess
the pattern of lipid-hsiRNA distribution within the adrenal
gland. As a general trend, higher levels of lipid-hsiRNA flu-
orescence were observed in the adrenal cortex compared to
the medulla (Figure 4C). The sterol-conjugated hsiRNAs
(Chol and LCA) presented the highest levels of internaliza-
tion in the adrenal cortex (Figure 4C), and the strongest ac-
tivity. Chol-hsiRNA silenced PpibmRNA up to 37%, while
LCA-hsiRNA reduced Ppib mRNA levels by 35% (Figure
4D, Supplementary Table S4). DCA-, DHA-, and unconju-
gated hsiRNA showed lower levels of internal fluorescence
in the adrenal cortex, and induced 24%, 15% and 11% Ppib
silencing, respectively (Figure 4D).
Uterus. HDL is an integral component of the reverse
cholesterol transport pathway, which transports lipids from
extrahepatic tissues to the liver for excretion or recycling.
Lipid transfer is commonly mediated by scavenger recep-
tor B1 (SR-BI), which is highly expressed in liver sinusoidal
endothelial cells, adrenal gland, ovary, and testis. There-
fore, wemonitored lipid-hsiRNAaccumulation and activity
within the uterus of female mice. DCA-, DHA-, LCA- and
unconjugated hsiRNAs showed punctate staining through-
out the lamina propria, with minimal staining of the en-
dometrial glands (Figure 4E). We measured significant lev-
els of Ppib silencing for both DHA-hsiRNA (35%) and un-
conjugated hsiRNA (33%) in biopsies from the uterine horn
(Figure 4F, Supplementary Table S4).
Kidneys. LCA-, DHA- and unconjugated hsiRNAs were
distributed similarly within the kidney cortex, staining both
proximal and distal convoluted tubules (Figure 4G). Minor
levels of fluorescence in the glomerulus were detected for
all three oligonucleotide conjugates, with DHA-hsiRNA
showing the most profound staining within the Bow-
man’s capsule (Figure 4G, closed arrow). Chol-hsiRNA
and DCA-hsiRNA were detected primarily within proxi-
mal convoluted tubules (Figure 4G). After measuring Ppib
mRNA levels in biopsies from the kidney cortex, we noted
parallels between accumulation and activity, with unconju-
gated hsiRNAs showing the highest level of silencing (78%)
(Figure 4H, Supplementary Table S4). We did not observe
any variability in biomarkers of kidney toxicity, includ-
ing blood urea nitrogen and creatinine levels (Supplemen-
tary Figure S5). We also monitored other standard serum
toxicological markers, including electrolytes (Ca2+, phos-
phate, Na+, K+), albumin, globulin, bilirubin, and glucose,
and saw no significant changes in total concentration after
hsiRNA,DHA-hsiRNA, orDCA-hsiRNA treatment (Sup-
plementary Figure S5).
Taken together, these data suggest that lipid-conjugated
hsiRNAs engage distinct lipid transport pathways and elicit
gene silencing in a variety of tissues with minimal sys-
temic toxicity. Interestingly, in some tissues, we observed a
non-linear relationship between hsiRNA tissue accumula-
tion and silencing efficacy, suggesting the presence of both
productive and non-productive internalization pathways.
This has been described for phosphorothioate-modified an-
tisense oligonucleotides, which are intrinsically more active
in hepatocytes than in the nonparenchymal cells of the liver
(25). The observed discrepancy between levels of hepatocyte
internalization after 48 h and mRNA silencing after 1 week
may indicate translocation of hsiRNAs from sinusoidal de-
pots into hepatocytes, or the presence of inherently more
potent endocytic pathways in hepatocytes (Figure 4A and
4B). Whether this extends to the kidney or other tissues is
unknown.
hsiRNAs are internalized independently of LDL recycling via
the LDL receptor
To probe the dependency of hsiRNA internalization
on lipoprotein receptor expression, we compared the
systemic biodistribution of an LDL-associated hsiRNA
(DCA-hsiRNA) and an HDL-associated hsiRNA (DHA-
hsiRNA) in both wild-type and LDLR-deficient mice.
We hypothesized that if LDL-associated hsiRNAs are
dependent on LDL endocytosis for internalization,
their biodistribution should be significantly perturbed
by LDLR depletion. LDLR-dependent internalization
into the liver has been described for both cholesterol-
and -tocopherol-conjugated duplex siRNAs (6,26). We
intravenously injected wild-type (C57BL/6J) and LDLR-
deficient (LDLR−/−) mice with DHA- or DCA-hsiRNA
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Figure 4. Distinct cellular uptake and efficacy patterns of lipid-conjugated hsiRNAs. Tissue-dependent internalization of lipid-hsiRNAs 48 h after a single,
subcutaneous injection (n = 3 mice, 20 mg kg−1) in (A) liver, (C) adrenal gland, (E) uterine horn and (G) kidney cortex. Cy3-labeled lipid-hsiRNAs (red),
nuclei stained with DAPI (blue). Arrowheads described in text. c: cortex; m: medulla; lp: lamina propria; eg: endometrial gland; pct: proximal convoluted
tubule; dct: distal convoluted tubule; g: glomerulus. Quantification of Ppib silencing by non-labeled lipid-hsiRNAs in (B) liver, (D) adrenal gland, (F)
uterine horn and (H) kidney cortex. Ppib mRNA levels were measured with QuantiGene 2.0 (Affymetrix) assay and normalized to a housekeeping gene,
Hprt. All data presented as percent of saline-treated control. All error bars represent mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
as calculated by one-way ANOVA with Tukey’s test for multiple comparisons.
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Figure 5. Mechanistic analysis of lipid-hsiRNA internalization in liver. (A) Guide strand quantification of Cy3-labeledDHA-hsiRNAs andDCA-hsiRNAs
in wild-type (C57BL/6J) and LDLR deficient animals after a single, intravenous injection (n = 3 mice, 10 mg kg−1) using a PNA hybridization-based
assay. Data presented as mean ± SD. (B) Hepatocyte internalization of Cy3-labeled DCA-hsiRNA in wild-type and LDLR deficient animals after a
single, intravenous injection (n = 3 mice, 10 mg kg−1). Image is representative. Cy3-labeled DCA-hsiRNAs (red), nuclei stained with DAPI (blue). (C)
Quantification of fluorescent signal from images acquired in (B). (D) Average retention times of Cy3-labeled DCA-hsiRNAs in mouse serum, 15 minutes
after IV injection (n = 2 mice, wild type or LDLR−/−). (E) Average peak integrations from lipoprotein profiles in (D). (F) Hepatocyte internalization of
Cy3-labeled blunt and asymmetric siRNAs (unconjugated, DCA-conjugated, or GalNAc-conjugated) after a single, subcutaneous injection (n = 3 mice,
20 mg kg−1), staining as described in (B). (G) Quantification of fluorescent signal from images acquired in (F).
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and quantified tissue accumulation by PNA hybridization
(n = 3, 10 mg kg−1). As expected, DHA-hsiRNA systemic
distribution and tissue internalization remained unchanged
between wild-type and LDLR−/− animals (Figure 5A, blue
bars). Unexpectedly, DCA-hsiRNA liver accumulation
increased two-fold in the absence of LDLR (Figure 5A,
purple bars). This finding suggests that LDL-associated
oligonucleotides are internalized in the liver by a mecha-
nism independent of lipoprotein endocytosis. To determine
if the observed increase in liver accumulation was cell-type
specific, we acquired high-resolution images of the liver
following subcutaneous administration of Cy3-labeled
DCA-hsiRNAs (n = 2, 10 mg kg−1). Hepatocyte fluores-
cence in LDLR−/- mice was visibly increased compared to
wild-type mice (Figure 5B). Image quantification revealed a
two-fold increase in fluorescence in mutant animals (Figure
5C). Taken together, these data suggest that hepatocyte
internalization of LDL-associated hsiRNAs can occur
independently of LDL endocytosis through LDLR.
hsiRNA hepatocyte internalization is facilitated by a
phosphorothioate-modified, single-stranded overhang
A defining feature of the hsiRNA constructs used in
this study is the presence of a 5-nt single-stranded,
phosphorothioate-modified (PS) overhang, which resem-
bles the fully PS, single-stranded backbone of conventional
antisense oligonucleotides (ASOs). Recent studies investi-
gating ASO internalization by hepatocytes have established
that the asialoglycoprotein receptor (ASGPR) contributes
to the uptake of unconjugated PS ASOs (27,28). Therefore,
one of the hepatocyte uptake pathways for DCA-hsiRNA
may be a receptor-mediated process that requires a single-
stranded, PS-modified overhang. To probe the structural re-
quirements for hepatocyte uptake, we compared the asym-
metric DCA-hsiRNA construct used throughout this study
with a 20-nt blunt-ended DCA-conjugated hsiRNA. Af-
ter analyzing the lipoprotein binding profiles of the asym-
metric and blunt DCA-hsiRNAs, we observed no differ-
ences in lipoprotein binding character (Figure 5D). Sim-
ilar to DCA-hsiRNA, blunt DCA-hsiRNA primarily as-
sociated with LDL (84.3%) and exhibited less affinity for
HDL (11.1%) and VLDL (4.8%) (Figure 5E). This result
provides further confirmation that lipoprotein association
is mediated by the lipid conjugate and suggests that these
compounds have comparable elimination half-lives in vivo.
However, following a single, subcutaneous injection of Cy3-
labeled blunt or asymmetric DCA-hsiRNA in wild-type
mice (n = 2, 20 mg kg−1), we observed significantly less
fluorescent signal in hepatocytes for blunt DCA-hsiRNA
(Figure 5F). This suggests that the single-stranded PS over-
hang contributes significantly to hepatocyte uptake. To de-
termine whether the presence of a single-stranded PS re-
gion is sufficient for unconjugated hsiRNA internalization,
we compared the liver distribution pattern of blunt and
asymmetric unconjugated hsiRNAs following administra-
tion to mice (n = 2, 20 mg kg−1). Although liver exposure
of unconjugated hsiRNAs is limited, due to its rapid elim-
ination half-life, we still observed a significant increase in
hepatocyte fluorescence of asymmetric compared to blunt
hsiRNA (Figure 5F, G). To further validate our finding
that single-stranded PS modifications enhance hepatocyte
uptake, we synthesized triantennary GalNAc-conjugated
blunt and asymmetric hsiRNAs. GalNAc-conjugated siR-
NAs are specifically and rapidly internalized in hepatocytes
through the ASGPR receptor. Here, we detected a marked
increase in GalNAc-mediated hepatocyte internalization in
the presence of a single-stranded PS tail (Figure 5F, G). The
asymmetric compounds containing phosphodiester rich tail
have reduced liver uptake and efficacy (data not shown),
suggesting that phosphorothioates, rather than structure,
principally contribute to enhance internalization. However,
this data should be interpreted with caution––a decrease
in phosphorothioate content negatively impacts the over-
all stability of oligonucleotides, which negatively affects ac-
tivity. While the amount of siRNA accumulation was dra-
matically enhanced by the presence of the phosphoroth-
ioated tail, the blunt compounds were similarly functional
in vivo (29). This finding suggests that phosphorothioate-
enhanced internalization may not contribute significantly
to productive uptake, at least in the short term. This is con-
sistent with most double-stranded GalNAc siRNAs conju-
gates that show robust efficacy in the clinic (30,31).
DISCUSSION
Here we demonstrate that changing the lipophilic modal-
ity attached to the fully chemically stabilized hsiRNA have
a profound impact on the hsiRNA tissue distribution pro-
file. In general, oligonucleotides tend to distribute to tissues
with filtering function, with higher blood flow and discon-
tinues, fenestrated endothelium: liver, spleen and kidneys
(2). Hydrophobically modified hsiRNAs, in general follow
these rules, with liver, spleen and kidney being primary tis-
sues for distribution. Although, the exact pattern of distri-
bution and relative liver/kidney ratio is heavily affected by
the nature of the conjugate. The more hydrophobic conju-
gates (cholesterol, DCA) preferentially deliver to the liver.
The less hydrophobic (DHA, LCA) conjugate shows much
lower liver accumulation and preferentially distribute to
kidneys.
Unconjugated hsiRNAs are quickly cleared by the kid-
neys (>85%) from the blood stream with a serum half-
life of a couple of minutes (32) (Biscans et al, 2018, NAR,
in this issue). The retained compounds mostly accumulate
in the kidney proximal tubule epithelia, likely due to en-
trapment during filtration. The compounds used in this
study contain ∼30% phosphorothioate (PS) modifications
(13 PS bonds out of 35 linkages). The kidney epithelia re-
tention is fully dependently on the presence of the phos-
phorothioates. Fully stabilized, non-PS modified hsiRNAs
are cleared semi-quantitatively with minimal levels of kid-
ney or any other tissue retention and are not detectable four
hours post injection (33,34). It is likely, that the observed
PS-dependent proximal tubule retention is similar in mech-
anism to antisense kidneys distribution. Short ASOs (12-16
bases, fully phosphorothioated) preferentially accumulate
in kidneys, which is a strategy that has been considered ex-
tensively for ASO-based modulation of gene expression in
kidney diseases (35). After intravenous or subcutaneous ad-
ministration, unconjugated hsiRNAs are rapidly filtered in
the kidneys from the blood into the glomerular space, where
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they are reabsorbed (likely via scavenger receptors) by prox-
imal tubule cells or excreted through the urine. Despite their
short residence time, unconjugated hsiRNAs achieve∼80%
target mRNA silencing in the kidney (Figure 4), providing
a simple strategy for modulation of gene expression in prox-
imal tubule epithelia (14). Interestingly, the level of kidney
silencing can be affected by presence of the hydrophobic flu-
orescent label, which negatively impacts silencing (Biscans
et al., 2018, NAR, in this issue).
The circulation half-life for lipid-conjugated hsiRNA is
significantly increased (32) likely due to spontaneous asso-
ciation with circulating lipoproteins. This increases plasma
half-life and promotes exposure to extra renal tissues. Dif-
ferent conjugates have a different impact on circulation
half-life with more lipophilic compounds having slower
clearance kinetics (32). Here, we explore if the observed
changes in both clearance and tissue distribution profiles
can be explained by changes in proteins in serum associ-
ated with different type of hsiRNAs. Indeed, we observe
that more hydrophobic hsiRNAs (Cholesterol, DCA) pref-
erentially bind LDL, while relatively less hydrophobic hsiR-
NAs (DHA, LCA) associate more with HDL and non-
conjugated hsiRNAs show limited serum binding.
The lack of significant serum protein association of non-
conjugated hsiRNA makes sense. Any minimal observed
retention is defined by phosphorothioates. It is well estab-
lished that both minimal number of phosphorothioate and
PS/PO ratio defines serum protein association of ASOs
(2). It is believed that a minimum of 16–18 PS in a row
is necessary to promote serum association, and thus liver
delivery, and shorter ASOs or ASOs with lower PS con-
tent show preferential kidney accumulation (20). The com-
pounds used in this study have only 13 PS bonds which rep-
resent ∼30% of nucleotide linkages, and thus are not ex-
pected to display significant serum binding.
The mouse plasma is significantly enriched in HDL com-
pared to LDL (6). In spite of that, chol-hsiRNAs, preferen-
tially associate with LDL indicating a much tighter binding
affinity. The serum binding profile was evaluated at 15 min-
utes post injection (∼half clearance rate, (32)). Interestingly,
Wolfrum et al. (6) showed similar affinity of chol-modified
siRNAs to LDL and HDL, although in a context of puri-
fied plasma in vitro. The differences in observed profiles are
likely related to the differences between in vitro and in vivo
steady state conditions.
In general, LDL-associated hsiRNAs enter into the en-
dogenous lipid transport pathway and are preferentially in-
ternalized in LDL receptor-enriched tissues, such as liver,
lung, and intestine. HDL-associated hsiRNAs are trans-
ported via reverse cholesterol transport and exhibit en-
hanced uptake and efficacy in SR-BI-enriched tissues, such
as adrenal gland and ovary. Moreover, the lipid transport
pathway engaged by lipid-conjugated hsiRNAs may be de-
termined a priori following measurement of lipid-siRNA
hydrophobicity. Thus in general, hydrophobicity correlates
with serum binding profile with more hydrophobic siR-
NAs associated with LDL and less hydrophobic with HDL,
which in parts predicts, to a significantly degree, tissues dis-
tribution profile, or at least liver/ kidney uptake ratio.
VLDL and LDL carry highly-nonpolar saturated triglyc-
erides and unsaturated cholesteryl esters, respectively, while
HDL carries cholesterol and unsaturated phospholipids
(relatively more polar). hsiRNAs equilibrate with circulat-
ing lipoproteins based on the solubility of the lipid conju-
gate in the lipoprotein core. A hypothesis that has been inde-
pendently corroborated by the observation that even when
highly-lipophilic Chol-siRNA conjugates are exogenously
loaded into HDL, they rapidly redistribute into LDL in
serum (6).
Several recent studies have postulated that lipid-
conjugated oligonucleotides leverage plasma albumin as
an endogenous carrier (7,36). Lipid-conjugated hsiRNAs
showed minimal binding to albumin in vivo (Figure 3),
despite robust affinity in vitro (Figure 3). This difference
between in vitro and in vivo, is again easily explained by the
relative affinities model. Lipid-conjugated siRNAs bind
tightly to purified albumin in vitro. In vivo, affinity to LDL
is significantly higher resulting in preferential binding and
no albumin distribution. Most prior studies were done
at 10 and 20 mg/kg dose levels, which is likely below the
LDL binding capacity and some albumin binding might be
observed at much higher dose levels when both LDL and
HDL will be saturated.
What is the role of LDL in lipophilic siRNA traffick-
ing: distribution, uptake or both? To answer this ques-
tion, we evaluated distribution of lipid-conjugated siRNA
in LDLR-deficient animals (37). We observed that both
clearance and tissue distribution profiles were almost iden-
tical. On top of it, LDLR-deficient animals showed ∼two-
fold enhancement in liver accumulation. Thus, it is likely
that while LDL binding is essential for clearance and distri-
bution, it is not a primary factor driving hsiRNA internal-
ization.
The conclusion that lipoprotein receptors do not prin-
cipally contribute to lipophilic siRNA cellular internal-
ization is consistent with previously reported data. Wol-
frum et al. demonstrated that the half clearance rate of
cholesterol-conjugated siRNAs was markedly faster (hours
vs days) than LDL and HDL (6). Both data sets are consis-
tent with the model, where lipoprotein-bound cholesterol-
siRNAs are carried by LDL and HDL particles, but pri-
marily internalized by an independent mechanism. There is
a body of literature suggesting that scavenger receptors may
be involved in cholesteryl ester internalization in LDL-R
negative mice (38), potentially explaining the observed (in
LDLR mutant) two-fold increase in lipophilic siRNA tis-
sue uptake.
Is hydrophobicity the only factor driving distribution and
tissue accumulation? In general, the correlation between
distribution and accumulation is great, it is not absolute.
Cholesterol and DCA show very similar hydrophobicity
and serum binding profiles with preferential LDL associ-
ation. While liver accumulation for both conjugates were
similar, extrahepatic delivery observed with DCA was sig-
nificantly higher than with cholesterol (up to 7-fold more
in lung and heart). These findings may be due to a tissue-
specific internalization mechanism and is a subject of fur-
ther investigation (see more in Biscans et al., 2018, NAR,
in this issue). It is possible that the identity of the conjugate
may contribute to cell surface adsorption, where internal-
ization may occur through an independent mechanism as
hypothesized by Crooke et al. (39). In addition, the nature
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of the conjugatemay impact efficiency of endosomal escape,
potentially explaining observed functional differences be-
tween lipophilic conjugates showing similar tissue accumu-
lation. (Biscans et al. for details, 2018, NAR, in this issue).
In this study we used fully chemically stabilized asym-
metric phosphorothioated (∼30%) siRNAs. Full chemical
stabilization is essential for conjugate mediated delivery (8)
and clinically advanced GalNAc conjugate compounds are
extensively stabilized (4,27,40). Cholesterol has been ex-
plored as a delivery modification for both blunt and asym-
metric compounds with conceptually similar pharmacoki-
netic behavior (33,41). With that said, phosphorothioates
are a primary force behind ASO delivery and significantly
enhances cholesterol mediated uptake in a mechanism sim-
ilar to that of ASOs (27,28).
To evaluate the relative impact of PS modifications
(∼30% content) on a conjugate mediated delivery in vivo,we
compared serum binding, distribution of blunt and asym-
metric fully chemically modified siRNAs conjugated to
GalNAc and DCA. While the overall serum binding pro-
file was similar, PS enriched siRNAs showed significantly
higher accumulation in liver independently of the presence
or nature of the conjugate. The liver accumulation was 10
to 100-fold higher in the context of PS-enriched asymmet-
ric compounds. These findings suggest that both lipoprotein
endocytosis and phosphorothioate modifications may con-
tribute to liver accumulation and cellular internalization co-
operatively. It is likely that LDL and HDL binding is essen-
tial for a slower clearance rate and enabling liver distribu-
tion, while phosphorothioatemodifications principally con-
tribute to cellular internalization. This observation is con-
sistent with previously reported cooperativity in liver inter-
nalization betweenGalNAc and PSmodifications (4,27,40).
It is important to note that while the level of accumu-
lation of the GalNAc-conjugate blunt siRNAs was lower
than asymmetric, it was sufficient to induce highly potent si-
lencing, consistently with most of clinically-active GalNac
conjugated-siRNAs being symmetric (4,27,40). In spite of
functional efficacy, we were surprised to see such a low level
of GalNAc-blunt siRNA liver accumulation. Most of the
clinical compounds are not blunt but carry a two base-
pair phosphorothioated overhang (42). It is possible that
these short PS-modified overhang might be functionally
contributing to hepatocytes internalization. It is also impor-
tant to note, that while GalNac blunt accumulates in liver
exclusively, GalNAc asymmetric PS-enriched compounds
deliver equally well to liver and kidneys (43). Thus, for selec-
tive liver targeting symmetric siRNA design might be pre-
ferred.
One of the interesting recent direction is the exploration
of biomimetic lipoprotein nanoparticles as siRNA deliv-
ery vehicles (44–49). Indeed, pre-formulation of cholesterol-
conjugated siRNAs with HDL enhanced in vivo efficacy
8- to 15-fold (44,45,50). In this study, partially modified
siRNAs were used, which are inherently unstable in serum
(51,52). It is likely that the observed enhancement in activ-
ity wasmostly due to stabilization of the siRNA in a protein
complex.
In the context of using fully chemically-stabilized hsiR-
NAs, complexing happens almost instantaneously in vivo,
thus harnessing endogenous lipoproteins to slowdown
clearance and enable wide tissue distribution. This ap-
proach allows use of chemically-defined entities, oligonu-
cleotides directly and circumvents the typical challenges as-
sociatedwith synthetic nanoparticles, including low loading
efficiency and yield (53), complex surface-modification pro-
cesses, and systemic toxicity (54).
Finally, an important advantage of lipid-conjugation is
that its impact on biodistribution is sequence-independent.
Thus, this strategy should behave analogously for the de-
livery of other small RNA cargo, including miRNAs, an-
tagomirs or CRISPR components. Although lipid conjuga-
tion as a delivery platform has many strengths, it also has
limitations, chief among them lack of targeted, cell type-
specific delivery. Thus, its likely applicability is limited to
targets and indications where clinically relevant target ex-
pression is limited to targetable tissue and its modulation in
clearance tissues like liver, kidney and spleen is not of con-
cern, as has recently been demonstrated for modulation of
sFLT1 in placenta (55) or myostatin in muscle (56).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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